CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 152 enrolled
Drug / intervention
FDG PET radiomic feature evaluationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04317313
NCT04317313N/ACompleted
CompareCT.gov

Synergistic Effect of 18F-FDG PET Radiomics and International Prognostic Index on Outcome Prediction in Diffuse Large B-cell Lymphoma

Second Affiliated Hospital, School of Medicine, Zhejiang University·observational·Posted Mar 23, 2020·Updated Oct 21, 2021

In Brief

An observational study evaluating FDG PET radiomic feature evaluation for Lymphoma, Large B-Cell, Diffuse. Completed, enrolled 152 participants across 1 site.

Detailed Summary

This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value to the International Prognostic Index (IPI).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Large B-Cell, Diffuse
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMar 23, 2020
Enrollment StartApr 1, 2020
Primary CompletionJul 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.3 years ago

Interventions

FDG PET radiomic feature evaluationother

A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features. In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature.